<DOC>
	<DOCNO>NCT00000376</DOCNO>
	<brief_summary>To develop effective combine cognitive therapy ( CT ) plus drug treatment patient drug-resistant depression ( DRD ) ( i.e. , depression refractory medication ) . To develop manual combine treatment DRD integrate three exist form CT ( CT depression , CT personality disorder , CT anxiety disorder ) , specifies intervention combine CT medication two therapist ( psychotherapist pharmacotherapist ) provide treatment . To obtain outpatient , randomize control , pilot data clinical value combine CT plus drug treatment , use standard antidepressant desipramine ( DMI ) , obtain effect size determine treatment merit investigation clinical trial . To develop therapist adherence measure combine treatment . Patients receive 1 2 treatment : CT plus DMI ( n = 18 ) DMI plus Clinical Management ( n = 12 ) . The first 6 18 CT plus DMI patient treat pre-pilot phase randomization begin . All treatment continue 6 month . The major assessment battery administer intake , 3 month , 6 month , follow-up 6 month later . All treatment closely monitor via audiotape supervision purpose develop refine CT plus drug treatment . The audiotape also use development adherence measure . The primary outcome measure Hamilton Rating Scale Depression score , Beck Depression Inventory score , percent patient achieve clinical remission symptom , percent show attrition treatment . Compliance treatment regimen also target measured outcome variable .</brief_summary>
	<brief_title>Cognitive Drug Therapy Drug-Resistant Depression</brief_title>
	<detailed_description>To develop effective combine cognitive therapy ( CT ) plus drug treatment patient drug-resistant depression ( DRD ) ( i.e. , depression refractory medication ) . To develop manual combine treatment DRD integrate three exist form CT ( CT depression , CT personality disorder , CT anxiety disorder ) , specifies intervention combine CT medication two therapist ( psychotherapist pharmacotherapist ) provide treatment . To obtain outpatient , randomize control , pilot data clinical value combine CT plus drug treatment , use standard antidepressant desipramine ( DMI ) , obtain effect size determine treatment merit investigation clinical trial . To develop therapist adherence measure combine treatment . Patients receive 1 2 treatment : CT plus DMI ( n = 18 ) DMI plus Clinical Management ( n = 12 ) . The first 6 18 CT plus DMI patient treat pre-pilot phase randomization begin . All treatment continue 6 month . The major assessment battery administer intake , 3 month , 6 month , follow-up 6 month later . All treatment closely monitor via audiotape supervision purpose develop refine CT plus drug treatment . The audiotape also use development adherence measure . The primary outcome measure Hamilton Rating Scale Depression score , Beck Depression Inventory score , percent patient achieve clinical remission symptom , percent show attrition treatment . Compliance treatment regimen also target measured outcome variable .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Personality Disorders</mesh_term>
	<mesh_term>Desipramine</mesh_term>
	<mesh_term>Antidepressive Agents , Tricyclic</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<criteria>Patients must : Drugresistant depression ( DRD ) .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2005</verification_date>
	<keyword>Adult</keyword>
	<keyword>Antidepressive Agents , Tricyclic</keyword>
	<keyword>Anxiety Disorders</keyword>
	<keyword>Cognitive Therapy</keyword>
	<keyword>Combined Modality Therapy</keyword>
	<keyword>Depression</keyword>
	<keyword>Desipramine</keyword>
	<keyword>Female</keyword>
	<keyword>Human</keyword>
	<keyword>Male</keyword>
	<keyword>Personality Disorders</keyword>
	<keyword>Pilot Projects</keyword>
	<keyword>Patient Care Team</keyword>
	<keyword>Antidepressive Agents , Tricyclic -- *therapeutic use</keyword>
	<keyword>Depression -- *therapy</keyword>
	<keyword>Depression -- drug therapy</keyword>
	<keyword>Desipramine -- *therapeutic use</keyword>
</DOC>